Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2021
Prognostic Utility of Breast Cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular CarcinomaRaquel Nunes, Tal Sella, Kai Treuner, et al.
Breast Cancer Research and Treatment|November 27, 2022
Adjuvant endocrine therapy non-initiation and non-persistence in young women with early-stage breast cancerShoshana M Rosenberg, Yue Zheng, Shari Gelber, et al.
Breast Cancer Research and Treatment|June 17, 2022
Outcomes after treatment of breast cancer during pregnancy including taxanes and/or granulocyte colony-stimulating factor use: findings from a multi-institutional retrospective analysisTal Sella, Pedro Exman, Siyang Ren, et al.
NPJ Breast Cancer|May 15, 2023
Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivorsTal Sella, Yue Zheng, Shoshana M Rosenberg, et al.
Cancer|October 26, 2023
Conception and pregnancy among women with a live birth after breast cancer treatment: A survey study of young breast cancer survivorsKimia Sorouri, Tal Sella, Shoshana M Rosenberg, et al.
Cancer|September 29, 2024
Breastfeeding experiences among young breast cancer survivors: A survey studyTal Sella, Kimia Sorouri, Shoshana M Rosenberg, et al.
Breast Cancer Research : BCR|February 5, 2020
ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosisAdi Zundelevich, Maya Dadiani, Smadar Kahana-Edwin, et al.
Breast Cancer Research : BCR|March 14, 2020
Correction to: ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosisAdi Zundelevich, Maya Dadiani, Smadar Kahana-Edwin, et al.
NPJ Breast Cancer|November 30, 2022
Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT)Tal Sella, Yue Zheng, Nabihah Tayob, et al.
Cancer|July 1, 2022
Body weight changes and associated predictors in a prospective cohort of young breast cancer survivorsTal Sella, Yue Zheng, Zhenying Tan-Wasielewski, et al.
Pageof 6